BridgeBio reported Phase 3 success for encaleret in autosomal dominant hypocalcemia type 1 (ADH1), meeting primary and key secondary endpoints with 76% of treated patients achieving serum and urine calcium targets at 24 weeks versus 4% on standard therapy. The company plans an FDA submission next year and positions encaleret as a potential new standard for this genetic endocrine disorder. The Phase 3 readout follows another positive late‑stage result for BridgeBio this week, reinforcing the company’s rare‑disease strategy. Management said encaleret was generally well tolerated and produced meaningful biochemical corrections without ongoing supplementation. Implication for rare‑disease developers: robust, well‑controlled Phase 3 results in niche indications can materially revalue platform companies and accelerate regulatory interactions; payers will scrutinize long‑term safety and real‑world efficacy given small patient populations. Investor note: BridgeBio’s twin late‑stage wins may catalyze partner interest and reposition the firm toward commercialization decisions and label negotiations over the next 12 months.